

RESEARCH

Open Access



Target capture sequencing reveals a monoclonal outbreak of respiratory syncytial virus B infections among adult hematologic patients

Claas Baier^{1*}, Jiabin Huang², Kerstin Reumann³, Daniela Indenbirken³, Felicitas Thol⁴, Christian Koenecke⁴, Ella Ebadi¹, Albert Heim⁵, Franz-Christoph Bange¹, Sibylle Haid⁶, Thomas Pietschmann^{6,7,8} and Nicole Fischer^{2*}

Abstract

Background: Respiratory syncytial virus (RSV) causes community-acquired respiratory tract infections during winter. However, outbreaks in hospitals also occur repeatedly. In particular, patients with hematologic malignancies are at an increased risk for a severe and potentially fatal course of RSV infection. Here we present the investigation of an RSV outbreak in a hematology ward for adults following the ORION statement.

Methods: An epidemiologic and molecular outbreak analysis was performed. We developed and employed a minimal oligonucleotide probe set in target capture probe sequencing that allows cost-effective RSV-A or -B capturing to reconstruct RSV genomes from clinical samples.

Results: Four adult patients were involved in the outbreak caused by RSV-B in March 2019. The enforcement of the pre-existing infection control measures by effective training of hospital staff contributed to a successful containment. PCR-based RSV screening on the ward enabled early detection of new cases and rapid isolation measures. The molecular analysis demonstrated that the outbreak sequences were highly related and distinct to other RSV-B strains circulating at the same time.

Conclusions: A multimodal infection control concept is essential for the timely detection and control of RSV outbreaks in patients with hematological disease. Among other measures, preventive screening for respiratory viruses is recommended. Furthermore, the integration of conventional and molecular epidemiology, such as whole-genome sequencing and variant calling, significantly contributes to the understanding of transmission pathways. Based on this, appropriate conclusions can be drawn for targeted prevention measures that have prepared us for the COVID-19 pandemic beyond the RSV approach described here.

Keywords: Respiratory syncytial virus, Outbreak, Hematology, Infection, Infection control, Capture probe sequencing, Molecular epidemiology

*Correspondence: baier.claas@mh-hannover.de; nfischer@uke.de

¹ Institute for Medical Microbiology and Hospital Epidemiology, Hannover Medical School (MHH), Carl-Neuberg-Straße 1, 30625 Hannover, Germany

² Institute for Medical Microbiology, Virology and Hygiene, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246 Hamburg, Germany

Full list of author information is available at the end of the article

Background

Respiratory syncytial virus (RSV) is an enveloped RNA virus. It is responsible for infections of the upper (URTI) and lower respiratory tract (LRTI) in a seasonal rhythm in countries with temperate climates [1–4]. The pathogen is primarily transmitted by



droplets from the respiratory tract and less often by contact. Aerosol transmission might play a role under certain circumstances as well [5]. The median incubation period is reported to be 4 to 5 days [6]. RSV outbreaks in hematology and oncology units (e.g., [7–10]) and other hospital settings [11] have been repeatedly reported in the last years. For infection control of RSV in healthcare facilities, several measures (e.g., isolation, personal protective equipment) are usually combined to prevent nosocomial spread [12]. Patients with a hematologic malignancy are at high risk for a severe RSV LRTI [13–16]. Especially, leukopenia seems to be a relevant risk factor for increased mortality [17].

Herein, we report the epidemiology, control and molecular investigation of a hospital outbreak caused by RSV-B affecting 4 adults on a hematology ward. In addition, we discuss how the existing infection control concept for RSV in hematology helped us in the coronavirus disease 2019 (COVID-19) pandemic.

Methods

Epidemiologic analysis

The epidemiologic analysis followed the principles of the ORION statement [18]. Patient charts, virology results and patient movement data were reviewed for data acquisition. In addition, a timeline was generated.

Case definition

An outbreak case was a patient from the affected ward with nosocomial acquisition of RSV in March 2019. Nosocomial acquisition was assumed when RSV was found on day 5 or later of the patient's stay on the ward.

Routine infection control measures for RSV

The infection control concept at our institution for hematology wards regarding RSV is summarized in Table 1. It was primarily shaped by the management of a previous RSV outbreak in a pediatric setting in our institution [10] and included a weekly PCR prevalence screening for asymptomatic patients [19]. This screening also addressed influenza.

Diagnostic virology

Combined nose/throat swabs or pharyngeal washes were taken for routine viral diagnostics. If available, material from the lower respiratory tract was suitable as well. Samples were processed at the Institute of Virology of the Hannover Medical School using the reverse transcription polymerase chain reaction (RT-PCR) based Panther Fusion[®] System (Hologic) [20]. This system allowed a semi-quantitative diagnostic using PCR cycle threshold (ct) values.

RNA extraction and cDNA synthesis

RNA was extracted from diagnostic samples using the Qiagen QIAamp MinElute Virus spin kit (Qiagen

Table 1 Basic infection control measures regarding RSV at the hematology ward

Isolation of RSV positive patients:

RSV positive patients were isolated (single room or grouping of patients, if more than one RSV patient was present). Isolation was kept until at least one respiratory specimen was tested negative by PCR or had a ct value ≥ 35 and the patient's medical condition improved

Prophylactic isolation of patients with respiratory symptoms:

Newly admitted patients with respiratory symptoms and already hospitalized patients with onset of respiratory symptoms were separated from other patients and tested for a panel of respiratory viruses

RSV specific contact and droplet precautions:

Visitors and HCWs wore a surgical mask, a gown and gloves whenever entering the room of a RSV positive patient. RSV infected patients were asked to stay preferably in their individual room and were instructed in hand hygiene. Outside of the room RSV positive patients wore surgical masks (e.g., during urgently necessary examinations)

Quarantine:

Other patients sharing a room with a patient who tested positive for RSV were put in quarantine for 8 days

Preemptive droplet precautions on the ward (universal masking):

All HCWs and visitors wore surgical masks at any time when on the ward during winter season (usually December to March). The same applied to all patients when they left their patient room. Visitors were intensively instructed in droplet precautions and hand hygiene

Prophylactic RSV Screening:

Newly admitted patients were tested for RSV/Influenza (admission screening). In addition, once weekly a RSV/Influenza screening for all patients on the ward took place (prevalence screening) [19, 20]

Pre-Season Audits/Training:

Training for HCWs provided by the infection control staff prior to the winter season

Protective isolation:

Nursing in separate rooms for selected patients (e.g., for hematology patients with an expected prolonged and severe leukopenia)

#57704) according to the instructions of the manufacturer. In brief, 125 µl of sample input was used and purified RNA was eluted in 50 µl water.

cDNA synthesis was performed according to the Superscript IV RT cDNA first-strand synthesis protocol (Thermo Fisher Scientific) involving RiboLock RNase Inhibitor and pdN6 random priming. 2nd strand synthesis was achieved with NEB Ultra RNA non-directional Second Strand Synthesis Module (New England Biolabs). cDNA was purified with Agencourt AMPure XP beads (Beckman Coulter Life Sciences).

Capture probe design

The initial step of the probe design pipeline is to select the representative strains of RSV that will be included in the analysis (see Additional files 1 and 2). A total of 1101 complete genomes were downloaded from GenBank [21] and aligned using the MAFFT tool [22]. We then entered the generated alignments into the BaitsTools tool [23] for bait generation. To reduce redundancy, we clustered the bait candidates with 80% identity using usearch [24] and kept only the centroid of each cluster. Finally, we filtered out the self-complementary baits and the baits that had at least 90% identity with other baits in a blastn [25] search. To ensure the quality of the final baits, we checked all final sequences for melting temperature and GC content. The outline of the capture probe design is illustrated in Additional file 3; sequences of the capture probes are provided in Additional file 4.

Library preparation, hybridization capture and sequencing

First, ds-cDNA was enzymatically fragmented using the SureSelect XT HS and XT Low Input Enzymatic Fragmentation Kit (Agilent). Library preparation was performed following the NEB protocol for using NEBNext DNA Ultra Library Prep Kit protocol E7370 (New England Biolabs) with the following modifications. For adaptor ligation, adaptors were diluted (1:10 or 1:25), if input cDNA was low, and USER™ enzyme volume was reduced to 2 µl. PCR cycles for library amplification were between 12 and 15 cycles depending on the amount of input cDNA.

Target capture enrichment was performed using xGen Lockdown Probes (see capture probe design) and reagents (Integrated DNA Technologies; IDT) according to the manufacturer's instructions. Briefly, DNA capture was achieved with 500 ng barcoded library, hybridization of the probes to the library was performed for 4 h at 65 °C. Subsequently, probe/cDNA mix was bound to washed Streptavidin beads (M-270 Streptavidin beads Thermo Scientific) for 45 min at 65 °C. Stringent Streptavidin beads washing steps (stringent washing buffer) were performed at 65 °C, followed by washing steps at

room temperature involving wash buffers I-III. Beads were resolved in 20 µl nuclease-free water and post-capture PCR enrichment was performed by using KAPA HiFi HotStart ReadyMix (Roche) with 2 µl NEXTFLEX ChIP Primer Mix for Illumina (PerkinElmer Applied Genomics). 20 µl captured DNA input diluted in 50 µl total volume was incubated 45 s at 98 °C, followed by 18 cycles of 15 s at 98 °C/30 s at 60 °C/30 s at 72 °C and final extension for 1 min at 72 °C. The library was purified using Agencourt AMPure XP beads (Beckman Coulter Life Sciences). Concentrations of all samples were measured with a Qubit 2.0 Fluorometer (Thermo Fisher Scientific) and fragment lengths distribution of the final libraries was analyzed with the DNA High Sensitivity Chip on an Agilent 2100 Bioanalyzer (Agilent Technologies). Sequencing was performed on the Illumina MiSeq platform (2 × 150-nt) paired reads and 3-5 Mio reads per sample.

Bioinformatic analysis

As a result of capture probe sequencing of 4 samples from the patients (P1 – P4) involved in the outbreak and of 3 control patients with RSV infections on different wards (C1–C3, reference cohort), total numbers of 2,394,484, 2,700,477, 2,790,882, 2,384,508, 2,200,353, 2,191,289, and 1,858,890 2 × 151-nucleotide (nt) paired-end reads were generated from the Illumina MiSeq sequencer by using the designed probes, respectively. Sequence raw data were subjected to quality control using FastQC [26]. Adapter sequences of the reads and bases with a score of less than Q30 were trimmed and any reads shorter than 36 nt removed using Trimmomatic v0.36. [27]. By removing the sequence reads originating from the host organism, a set of non-host high-quality paired-end reads were prepared and fed into the SPAdes assembler (version 3.7.1), resulting in complete genomes for all patients, respectively. For each sample, we mapped the non-host reads to its newly assembled genome using Novoalign V3.07.00 (<http://www.novocraft.com>) with the parameters '-r Random -l 20 -g 40 -x 20 -t 100 -k', resulting in the alignment file. Then we used the tools samtools [28] and MarkDuplicate available in Picard tools (<http://broadinstitute.github.io/picard/>) [29] to sort the alignments and remove duplicate sequences from the alignment. The derived alignment was fed into V-Phaser2 [30] for intra-individual single nucleotide variation (iSNV) identification. In the variant identification, we only considered variants supported by at least five reads on each strand, and the ratio of the number of reads on the two strands is smaller than 10. Furthermore, the reads that mapped twice or more on the sequence were discarded. In the end, the iSNVs whose allele frequency is smaller than 0.5% were filtered out from the final results.

re-instructed to use personal protective equipment (primarily surgical masks) and to perform hygienic hand disinfection. Moreover, we monitored hand hygiene adherence by ad hoc direct observation (compliance rate of about 70%) and gave feedback talks.

All RSV-positive tested patients were immediately isolated.

Molecular analysis

To confirm our hypothesis that all 4 patients were infected with the identical RSV strain and that these transmissions occurred on the ward, we performed RSV target capture sequencing using enrichment techniques in these 4 patients. In parallel, we examined 3 patients with RSV identified at the same time on different wards to test the hypothesis that this was not a common RSV genotype that was repeatedly introduced to the ward. These 3 control patients allowed us to assess the variability of RSV circulating in the same geographic area during this time period. We were able to determine the whole genome sequence of 15,185 nucleotides from all 7 specimens included. Detailed information on the sequencing of each genome and the coverage can be found in Additional files 5 and 6. Phylogenetic classification identified both patient and control genomes as RSV-B (Fig. 2). The RSV sequences of the 4 outbreak patients were identical to each other and had 83–87 single nucleotide polymorphisms to the RSV-B controls (see Additional file 7).

Discussion

We investigated the epidemiologic and molecular characteristics of a RSV-B cluster affecting adult hematologic patients.

Transmission between patients, in particular patients sharing a room, is mainly conducted by droplets in RSV outbreaks [10, 31, 32]. Therefore, we assumed a direct transmission from patient 1 to patient 2 due to the shared room occupancy. The initial RSV infection source of patient 1, however, remained unclear. Patient 1 received visits and had contact to the ward's staff for several days prior to acquisition. However, visitors and staff were urged to wear surgical masks during patient contact. Because the time interval between the positive test results of patients 1 and 2 was relatively short, a shared unknown source of infection would also be conceivable.

Interestingly, patients 2 and 3 shared for several hours one patient room before patient 2 was placed in quarantine in a single room following the positive test result of patient 1. Patient 3 tested positive 5 days later at a prevalence screening. This temporal sequence agrees well with the RSV incubation period. Thus, patient-to-patient contact could have also been the transmission route for patient 3. Patient 4 did not share a room with any other

outbreak patients. Therefore, direct transmission due to co-hospitalization in the same patient room can be excluded. However, it is conceivable that there was a contact of patient 4 on the hallway or in the ward lounge with patient 3 before spatial isolation of patient 3. A random and independent occurrence of different RSV strains was implausible to us because of the clear nosocomial occurrence and the overlapping time periods. This was further confirmed by virus sequencing, which confirmed infection of the patients by the same viral strain (see below).


To our surprise, the cluster occurred although several control measures recommended for hematology wards were already in place [33, 34]. These control measures addressed potential sources (patients, healthcare workers, visitors) and transmission pathways (droplets, contact) of RSV in the hospital setting, as previously described in other outbreaks [8, 10, 31].

A core measure containing the spread by droplets is universal masking (surgical masks or FFP2/KN95). Noteworthy, this measure has been widely adopted in hospitals in the current COVID-19 pandemic and has also shown a reduction of nosocomial RSV and influenza as a side effect [35]. Starting March 2020, we used strict universal masking (staff and patients) in the COVID-19 pandemic with the hematologic ward affected by the outbreak described here being a role model for other wards.

Nursing in separate rooms of selected hematology patients (e.g., patients with an expected prolonged and severe leucopenia) is another important measure and can contribute to outbreak prevention and containment.

In our case, the outbreak control management focused explicitly on enforcing the already existing measures, thereby successfully containing the outbreak. The established PCR-based screening program (including influenza) [19] was helpful in rapid detection of the index patient and patients 3 and 4, both being asymptomatic at the time of the PCR screening. The infection control concept of prevalence and admission screening has also been widely adopted during the COVID-19 pandemic in healthcare facilities. Moreover, it might be useful to extend a screening panel to other respiratory viruses such as human metapneumovirus, which can also cause (severe) morbidity and mortality in immunocompromised hematology patients.

Integrating molecular sequence analysis with temporal and spatial information from classical epidemiology significantly increases the understanding of outbreak events. Building on this, we tested and confirmed our epidemiological hypothesis regarding the chain of transmission by target capture sequencing. The RSV-B isolates from the 4 patients were identical but significantly distinct from other RSV-B isolates found during the same time period in our institution. Given the molecular and epidemiologic



analysis, we assume that patient-to-patient transmission among patients 1 to 3 is likely and that patient 4 is part of the outbreak as well. The transmission route in the latter patient, however, remains unclear. Initial introduction of the RSV outbreak strain by a point source (e.g., an oligosymptomatic infected relative or healthcare worker) is possible. This outbreak investigation illustrates that a molecular characterization is highly valuable to elucidate the potential transmission pathways in RSV outbreaks.

We followed the ORION statement for outbreak reporting [18] in many points in this report. However, we

did not focus on evaluating the economic impact of the outbreak here (for instance due to reduced bed capacity because of isolation measures). Moreover, the prophylactic PCR-based screening we used is a resource-intensive measure, and we are aware that this might not be available in other settings.

Conclusions

Although the importance of prevention and rapid containment of RSV outbreaks in hematology is well known and mostly comprehensive infection control measures

are in place, transmissions may occur. We therefore underline that existing measures must be enforced by intensive training sessions for the wards' staff and the patients' visitors. Furthermore, prophylactic RSV screening is crucial for outbreak containment and even prevention. Integration of molecular analyses, such as high-resolution whole-genome sequencing, with classical epidemiological information on temporal and spatial events, can be instrumental in resolving outbreaks. The infection control management described here is—beyond RSV—essential in the COVID-19 pandemic.

Abbreviations

RSV: Respiratory syncytial virus; URTI: Upper respiratory tract infection; LRTI: Lower respiratory tract infection; COVID-19: Coronavirus disease 2019; RT-PCR: Reverse transcription polymerase chain reaction; HCWs: Health care workers.

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s13756-022-01120-z>.

Additional file 1. GenBank accession numbers of RSV-A genomes applied in probe design

Additional file 2. GenBank accession numbers of RSV-B genomes applied in probe design

Additional file 3. Workflow of probe design pipeline

Additional file 4. Fasta files of all RSV capture probes

Additional file 5. Summary of short read sequencing results

Additional file 6. Coverage profiles of the RSV sequences obtained by target capture probe sequencing

Additional file 7. Overview of SNPs of all RSV sequences obtained

Acknowledgements

Not applicable.

Author contributions

All authors contributed to the manuscript according to the ICMJE (International Committee of Medical Journal Editors) recommendations: All authors were involved in data acquisition, analysis and interpretation. NF, JH, KR, DI, SH and TP were involved in the molecular analysis. CB, F-CB, EE, CK and FT were involved in the outbreak management and epidemiologic workup. AH carried out routine RSV diagnostic. CB and NF wrote the manuscript. All authors have read and approved the final manuscript.

Funding

TP is funded by Germany's Excellence Strategy—EXC 2155 "RESIST"—Project ID 390874280.

Availability of data and materials

The datasets generated during and/or analyzed during the current study are available from the corresponding authors on reasonable request. Patient data used in this study is confidential according to the German data privacy act, the ethics committee and the data protection commissioner of the Hannover Medical School. To protect patient confidentiality and participant's privacy, data used for this study can be obtained in anonymous form only according to the data privacy act.

Declarations

Ethics approval and consent to participate

We obtained ethical approval for this study from the ethics committee of the Hannover Medical School (Number 8456_BO_K_2019). Being a retrospective study, the need of informed consent was waived by the ethics committee and the data protection commissioner of Hannover Medical School.

Consent for publication

Not applicable (No individual details such as images or videos are included).

Competing interests

The authors declare that they have no competing interests.

Author details

¹Institute for Medical Microbiology and Hospital Epidemiology, Hannover Medical School (MHH), Carl-Neuberg-Straße 1, 30625 Hannover, Germany. ²Institute for Medical Microbiology, Virology and Hygiene, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246 Hamburg, Germany. ³Leibniz Institute for Experimental Virology, Martinistraße 52, 20251 Hamburg, Germany. ⁴Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School (MHH), Carl-Neuberg-Straße 1, 30625 Hannover, Germany. ⁵Institute of Virology, Hannover Medical School (MHH), Carl-Neuberg-Str. 1, 30625 Hannover, Germany. ⁶Institute for Experimental Virology; Twincore-Centre for Experimental and Clinical Infection Research; a joint venture of Hannover Medical School (MHH) and Helmholtz Centre for Infection Research (HZI), Feodor-Lynen-Straße 7, 30625 Hannover, Germany. ⁷Cluster of Excellence RESIST (EXC 2155), Hannover Medical School, Carl-Neuberg-Straße 1, 30625 Hannover, Germany. ⁸German Center for Infection Research (DZIF), Partner Site Hannover-Braunschweig, 30625 Hannover, Germany.

Received: 9 January 2022 Accepted: 24 May 2022

Published online: 21 June 2022

References

- Borchers AT, Chang C, Gershwin ME, Gershwin LJ. Respiratory syncytial virus—a comprehensive review. *Clin Rev Allergy Immunol*. 2013;45:331–79. <https://doi.org/10.1007/s12016-013-8368-9>.
- Rodriguez R, Ramilo O. Respiratory syncytial virus: how, why and what to do. *J Infect*. 2014;68(Suppl 1):S115–8. <https://doi.org/10.1016/j.jinf.2013.09.021>.
- Griffiths C, Drews SJ, Marchant DJ. Respiratory syncytial virus: Infection, detection, and new options for prevention and treatment. *Clin Microbiol Rev*. 2017;30:277–319. <https://doi.org/10.1128/CMR.00010-16>.
- Nam HH, Ison MG. Respiratory syncytial virus infection in adults. *BMJ*. 2019;366:15021. <https://doi.org/10.1136/bmj.15021>.
- Kulkarni H, Smith CM, Lee DDH, Hirst RA, Easton AJ, O'Callaghan C. Evidence of respiratory syncytial virus spread by aerosol. Time to revisit infection control strategies? *Am J Respir Crit Care Med*. 2016;194:308–16. <https://doi.org/10.1164/rccm.201509-1833OC>.
- Lessler J, Reich NG, Brookmeyer R, Perl TM, Nelson KE, Cummings DA. Incubation periods of acute respiratory viral infections: a systematic review. *Lancet Infect Dis*. 2009;9:291–300. [https://doi.org/10.1016/S1473-3099\(09\)70069-6](https://doi.org/10.1016/S1473-3099(09)70069-6).
- Kelly SG, Metzger K, Bolon MK, Silkaitis C, Mielnicki M, Cullen J, et al. Respiratory syncytial virus outbreak on an adult stem cell transplant unit. *Am J Infect Control*. 2016. <https://doi.org/10.1016/j.ajic.2016.03.075>.
- Inkster T, Ferguson K, Edwardson A, Gunson R, Soutar R. Consecutive yearly outbreaks of respiratory syncytial virus in a haemato-oncology ward and efficacy of infection control measures. *J Hosp Infect*. 2017;96:353–9. <https://doi.org/10.1016/j.jhin.2017.05.002>.
- Nabeya D, Kinjo T, Parrott GL, Uehara A, Motooka D, Nakamura S, et al. The clinical and phylogenetic investigation for a nosocomial outbreak of respiratory syncytial virus infection in an adult hemato-oncology unit. *J Med Virol*. 2017;89:1364–72. <https://doi.org/10.1002/jmv.24800>.
- Baier C, Haid S, Beilken A, Behnert A, Wetzke M, Brown RJP, et al. Molecular characteristics and successful management of a respiratory syncytial

- virus outbreak among pediatric patients with hemato-oncological disease. *Antimicrob Resist Infect Control*. 2018;7:21. <https://doi.org/10.1186/s13756-018-0316-2>.
11. Ryu S, Kim BI, Chun BC. An outbreak of respiratory tract infection due to Respiratory Syncytial Virus-B in a postpartum center. *J Infect Chemother*. 2018;24:689–94. <https://doi.org/10.1016/j.jiac.2018.06.010>.
 12. French CE, McKenzie BC, Coope C, Rajanaidu S, Paranthaman K, Pebody R, et al. Risk of nosocomial respiratory syncytial virus infection and effectiveness of control measures to prevent transmission events: a systematic review. *Influenza Other Respi Viruses*. 2016;10:268–90. <https://doi.org/10.1111/irv.12379>.
 13. Hijano DR, Maron G, Hayden RT. Respiratory viral infections in patients with cancer or undergoing hematopoietic cell transplant. *Front Microbiol*. 2018;9:3097. <https://doi.org/10.3389/fmicb.2018.03097>.
 14. Khawaja F, Chemaly RF. Respiratory syncytial virus in hematopoietic cell transplant recipients and patients with hematologic malignancies. *Haematologica*. 2019;104:1322–31. <https://doi.org/10.3324/haematol.2018.215152>.
 15. Vakil E, Sheshadri A, Faiz SA, Shah DP, Zhu Y, Li L, et al. Risk factors for mortality after respiratory syncytial virus lower respiratory tract infection in adults with hematologic malignancies. *Transpl Infect Dis*. 2018;20:e12994. <https://doi.org/10.1111/tid.12994>.
 16. Chemaly RF, Shah DP, Boeckh MJ. Management of respiratory viral infections in hematopoietic cell transplant recipients and patients with hematologic malignancies. *Clin Infect Dis*. 2014;59(Suppl 5):S344–51. <https://doi.org/10.1093/cid/ciu623>.
 17. Azzi JM, Kyvernitakis A, Shah DP, El Haddad L, Mahajan SN, Ghantaji SS, et al. Leukopenia and lack of ribavirin predict poor outcomes in patients with haematological malignancies and respiratory syncytial virus infection. *J Antimicrob Chemother*. 2018;73:3162–9. <https://doi.org/10.1093/jac/dky311>.
 18. Stone SP, Cooper BS, Kibbler CC, Cookson BD, Roberts JA, Medley GF, et al. The ORION statement: guidelines for transparent reporting of outbreak reports and intervention studies of nosocomial infection. *Lancet Infect Dis*. 2007;7:282–8. [https://doi.org/10.1016/S1473-3099\(07\)70082-8](https://doi.org/10.1016/S1473-3099(07)70082-8).
 19. Baier C, Linderkamp C, Beilken A, Thol F, Heuser M, Ebadi E, et al. Influenza and respiratory syncytial virus screening for the detection of asymptotically infected patients in hematology and oncology. *GMS Hyg Infect Control*. 2018;13:Doc08. <https://doi.org/10.3205/dgkh000314>.
 20. Ganzenmueller T, Kaiser R, Baier C, Wehrhane M, Hilfrich B, Witthuhn J, et al. Comparison of the performance of the Panther Fusion respiratory virus panel to R-Gene and laboratory developed tests for diagnostic and hygiene screening specimens from the upper and lower respiratory tract. *J Med Microbiol*. 2020;69:427–35. <https://doi.org/10.1099/jmm.0.001133>.
 21. Benson DA, Cavanaugh M, Clark K, Karsch-Mizrachi I, Ostell J, Pruitt KD, et al. GenBank. *Nucleic Acids Res*. 2018;46:D41–7. <https://doi.org/10.1093/nar/gkx1094>.
 22. Katoh K, Standley DM. MAFFT multiple sequence alignment software version 7: improvements in performance and usability. *Mol Biol Evol*. 2013;30:772–80. <https://doi.org/10.1093/molbev/mst010>.
 23. Campaña MG. BaitsTools: software for hybridization capture bait design. *Mol Ecol Resour*. 2018;18:356–61. <https://doi.org/10.1111/1755-0998.12721>.
 24. Edgar RC. Search and clustering orders of magnitude faster than BLAST. *Bioinformatics*. 2010;26:2460–1. <https://doi.org/10.1093/bioinformatics/btq461>.
 25. Camacho C, Coulouris G, Avagyan V, Ma N, Papadopoulos J, Bealer K, et al. BLAST+: architecture and applications. *BMC Bioinformatics*. 2009;10:421. <https://doi.org/10.1186/1471-2105-10-421>.
 26. Andrews S. FastQC: a quality control tool for high throughput sequence data. <http://www.bioinformatics.babraham.ac.uk/projects/fastqc/>. Accessed 19 Dec 2021.
 27. Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. *Bioinformatics*. 2014;30:2114–20. <https://doi.org/10.1093/bioinformatics/btu170>.
 28. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The Sequence Alignment/Map format and SAMtools. *Bioinformatics*. 2009;25:2078–9. <https://doi.org/10.1093/bioinformatics/btp352>.
 29. BROAD INSTITUTE. Picard Toolkit. GitHub repository. <http://broadinstitute.github.io/picard>. 2019. Accessed 19 Dec 2021.
 30. Yang X, Charlebois P, Macalalad A, Henn MR, Zody MC. V-Phaser 2: variant inference for viral populations. *BMC Genomics*. 2013;14:674. <https://doi.org/10.1186/1471-2164-14-674>.
 31. Lehnert N, Schnitzler P, Geis S, Puthenparambil J, Benz MA, Alber B, et al. Risk factors and containment of respiratory syncytial virus outbreak in a hematology and transplant unit. *Bone Marrow Transplant*. 2013;48:1548–53. <https://doi.org/10.1038/bmt.2013.94>.
 32. Jensen TO, Stelzer-Braid S, Willenborg C, Cheung C, Andresen D, Rawlinson W, et al. Outbreak of respiratory syncytial virus (RSV) infection in immunocompromised adults on a hematology ward. *J Med Virol*. 2016;88:1827–31. <https://doi.org/10.1002/jmv.24521>.
 33. Hirsch HH, Martino R, Ward KN, Boeckh M, Einsele H, Ljungman P. Fourth European conference on infections in leukaemia (ECL-4): guidelines for diagnosis and treatment of human respiratory syncytial virus, parainfluenza virus, metapneumovirus, rhinovirus, and coronavirus. *Clin Infect Dis*. 2013;56:258–66. <https://doi.org/10.1093/cid/cis844>.
 34. Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. *Biol Blood Marrow Transplant*. 2009;15:1143–238. <https://doi.org/10.1016/j.bbmt.2009.06.019>.
 35. Wong S-C, Lam GK-M, AuYeung CH-Y, Chan VW-M, Wong NL-D, So SY-C, et al. Absence of nosocomial influenza and respiratory syncytial virus infection in the coronavirus disease 2019 (COVID-19) era: implication of universal masking in hospitals. *Infect Control Hosp Epidemiol*. 2021;42:218–21. <https://doi.org/10.1017/ice.2020.425>.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

